Understanding an Increasingly Complex Treatment Landscape in Urothelial Carcinoma: Guidance for Frontline Oncology Practitioners

Download All
A comprehensive educational program to equip oncology nurses, nurse practitioners, physician assistants, and pharmacists with up-to-date information to incorporate new and emerging therapies into clinical practice.
Kinjal Patel, PharmD, BCOP
person default
Kinjal Patel, PharmD, BCOP
Susan Roethke, CRNP, MSN, AOCN, ANP-BC

Interactive Virtual Presentations

Listen as Kinjal Patel, PharmD, BCOP, discusses the most recent data on new treatment options for patients with advanced or metastatic urothelial carcinoma.

Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 13, 2020 Expired: November 12, 2021

Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication and treatment considerations when using enfortumab vedotin for patients with advanced or metastatic urothelial carcinoma.

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Pharmacists: 0.25 contact hours (0.025 CEUs) Registered Nurses: 0.25 Nursing contact hours Released: December 16, 2020 Expired: December 15, 2021

Kinjal Patel, PharmD, BCOP, discusses the mechanism of action, indication, and treatment considerations when using erdafitinib for patients with advanced or metastatic urothelial carcinoma.

person default Kinjal Patel, PharmD, BCOP Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 1, 2020 Expired: November 30, 2021

Review important nursing considerations and tips for educating patients undergoing treatment with erdafitinib or enfortumab vedotin for advanced urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: November 30, 2020 Expired: November 29, 2021

Listen as Susan K. Roethke, CRNP, MSN, AOCNP, ANP-BC, discusses optimal management of common AEs associated with enfortumab vedotin treatment in patients with advanced or metastatic urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 22, 2020 Expired: December 21, 2021

Listen as Susan K. Roethke, CRNP, MSN, AOCNP, ANP-BC, discusses optimal management of common AEs associated with erdafitinib treatment in patients with advanced or metastatic urothelial carcinoma.

Susan Roethke, CRNP, MSN, AOCN, ANP-BC Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: December 21, 2020 Expired: December 20, 2021
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Astellas and Seattle Genetics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue